Livzon Pharmaceutical Group Inc. (SZSE:000513) commences share repurchases on January 4, 2021, under the program mandated by the shareholders in the Extraordinary General Meeting held on December 23, 2020. As per the mandate, the company is authorized to repurchase up to 31,986,421 H shares, representing 10% of its issued share capital. The purpose of the program is to enhance the long-term investment value of the company’s shares. The repurchased shares will be cancelled. The repurchases will be made out of the internal sources funds legally available for such purpose in accordance with its Bye-Laws and the applicable laws of PRC and the Hong Kong Listing Rules. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is carried out to the full extent, unless varied or revoked in a General Meeting. As of December 23, 2020, the company had 944,712,340 shares in issue, which are comprising of 624,848,123 A shares and 319,864,217 H shares.